How to Reduce ApoB Naturally Using a Functional Medicine Approach

When I assess someone’s risk for cardiovascular disease, one of the first things I look at is their ApoB level. ApoB, or apolipoprotein B, is a critical marker that tells us how many atherogenic particles are circulating in the bloodstream. It’s a much more precise indicator of cardiovascular risk than traditional LDL cholesterol.

Yet this marker is rarely assessed with standard testing through your GP.

In functional medicine, we use this marker not just as a risk assessment tool but as a starting point to explore deeper metabolic, hormonal, and inflammatory imbalances. Understanding what drives ApoB higher allows us to create a plan rooted in nutrition, lifestyle, and targeted supplementation.

What Is ApoB and What Does It Mean When It’s High?

ApoB is a protein made primarily in the liver (as ApoB-100) that attaches to various cholesterol-carrying particles in the blood. These particles, including LDL, VLDL, IDL, remnant cholesterol, lipoprotein(a), and others are known to contribute to the buildup of plaque in the arteries, a process known as atherosclerosis (1,2).

What makes ApoB unique is that each of these potentially harmful particles carries exactly one ApoB protein, meaning ApoB acts like a headcount for all the cholesterol particles capable of damaging blood vessels (1).

This is important because traditional tests like LDL-C (often called “bad cholesterol”) only estimate the total amount of cholesterol in the blood, not how many particles are carrying it, or how small and dense they are. Yet it’s those small, dense, and more numerous particles that pose the greatest risk. In fact, someone can have a “normal” LDL level but still have a high number of these atherogenic particles, which only becomes clear when ApoB is measured (1,3).

For that reason, many experts now consider ApoB to be a superior predictor of heart disease compared to LDL cholesterol alone, especially in people with metabolic issues like insulin resistance or type 2 diabetes (3).

Reference Ranges and Functional Targets

High ApoB itself doesn’t cause symptoms, but it often reflects underlying metabolic dysfunction. In clinical practice, I often see it associated with:

• Weight gain around the abdomen
• Poor blood sugar control or insulin resistance
• Fatigue and low physical endurance
• Erectile dysfunction and circulation issues
• High blood pressure
• Cognitive issues like brain fog

These symptoms are clues that the vascular and metabolic systems need support. Equally some of the factors that raise ApoB are genetic and this should also be considered.

Conditions Connected to High ApoB

High ApoB is often driven by a combination of lifestyle factors and genetic predisposition. In some cases, it may result from:

• Insulin resistance or type 2 diabetes
• Hypothyroidism
• Liver dysfunction, particularly non-alcoholic fatty liver disease
• Chronic low-grade inflammation
• Excess intake of refined carbohydrates or industrial seed oils

Left unaddressed, a high ApoB level significantly increases the risk of atherosclerosis, coronary artery disease, peripheral artery disease, and even stroke (7).

Given the influence of other physiological imbalances, it is critical to take a more holistic approach. Simply lowering ApoB through medications and ignoring imbalances such as, insulin resistance, inflammation, liver dysfunction etc will have only minor influences on lowering ones cardiometabolic risk.

Nutrition and Lifestyle Interventions to help lower ApoB

I often begin with dietary changes that are known to support a healthy lipid profile.

Adapting nutrition habits accordingly to support more optimal body composition.

This often means managing overall caloric intake. Sometimes in a more direct analytic way and other times in an indirect way, simply though making changes like the ones listed below:

• A Mediterranean-style diet, rich in extra virgin olive oil, nuts, oily fish, and colourful vegetables. The goal is to be predominantly wholefood in your choices.
• Cutting back on processed foods, sugar, and trans fats.
• Replacing industrial seed oils (like corn and soybean oil) and more saturated fats (like palm, coconut, cheese, butter, cream etc) with foods higher in monounsaturated fats like olive oil and avocado and some emphasis on omega 3 fats from fish, certain seeds/nuts etc.
• Including soluble fibre sources such as oats, flaxseed, legumes, and psyllium husk.
• Minimising alcohol intake

In addition to broad changes to diet, we use targeted therapeutic foods to support the management of LDL and ApoB. These include oily fish, olive oil, avocado, psyllium husk, nuts, ginger, fruits rich in pectin, green team legumes, soy products and foods rich in beta glucans like oats.

Alongside dietary changes, regular movement, quality sleep, and stress regulation are essential. These support insulin sensitivity, manage stress hormones, supporting recovery and energy levels. All of which can aid the dietary choices we make.

Evidence-Based Supplement Support

There are several nutritional supplements I often consider for clients with elevated ApoB, based on both clinical experience and scientific literature:

• Omega-3 fatty acids (EPA/DHA) – High doses (2–4g/day) have been shown to reduce ApoB levels and improve overall cardiovascular health (8, 9).
• Berberine – Acts similarly to metformin, supporting blood sugar control and lipid metabolism (10,11).
• Red yeast rice – Contains monacolin K, which functions like a natural statin and can lower ApoB-containing lipoproteins (12). Although I use this sparingly with clients as for some sensitive people they may experience similar side effects to statin medications.
• Plant sterols and stanols – Help block the absorption of dietary cholesterol and have modest effects on ApoB (13).

Further Investigations Worth Considering

To get a complete picture of what’s driving elevated ApoB, I often recommend additional tests. In fact, with most clients, we like to run a broader assessment at the start, taking a much more holistic approach from the beginning:

• Lipoprotein(a) — to assess genetic cardiovascular risk.
• Insulin and HOMA-IR — to evaluate insulin resistance.
• hs-CRP — for inflammation.
• Full thyroid panel — to rule out hypothyroidism.
• Liver function tests – to understand if there is evidence of fatty liver or sluggish liver function impacting on cholesterol production and excretion.
• Genetic markers like ApoE genotype or familial hypercholesterolemia profiles.
• Full lipid panels (Total cholesterol, HDL, LDL) with the addition of small LDL.

These insights help tailor the approach, ensuring we’re targeting the root cause rather than just treating a number. Check out our Functional Health Assessment. We offer this as a starting point for new clients or part of an annual review. This particular service is available to clients throughout the UK.

Conclusion and Next Steps

Elevated ApoB is one of the most powerful predictors of cardiovascular disease, but it’s also one of the most modifiable when we approach it from a functional and systems-based perspective.

If you’ve been told your ApoB is high or you’re concerned about your heart health, I’d encourage you to take a closer look at what might be driving it.

Through functional testing, nutritional therapy, and personalised lifestyle interventions, it’s entirely possible to bring ApoB into a healthy range, whilst also lowering multiple other risk factors in the process.

To learn more about how I approach cardiovascular and metabolic health, visit my Functional Medicine page.

References

1. Sniderman, A. D., et al. (2019). Apolipoprotein B particles and cardiovascular disease: A narrative review. JAMA Cardiology, 4(12), 1287–1295.
2. Carr, S. S., et al. (2019). Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology, 51(2), 148–154.
3. Fonseca, L., et al. (2020). Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol. Lipids Health Dis., 19(1), 132.
4. Walldius, G., & Jungner, I. (2006). The apoB/apoA-I ratio: A strong, new risk factor for cardiovascular disease. Journal of Internal Medicine, 259(5), 493–519.
5. Ference, B. A., et al. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. European Heart Journal, 38(32), 2459–2472.
6. O’Donnell, M. J., et al. (2016). Global and regional effects of potentially modifiable risk factors associated with acute stroke. The Lancet, 388(10046), 761–775.
7. Estruch, R., et al. (2018). Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. New England Journal of Medicine, 378, e34.
8. Skulas-Ray, A.C., Alaupovic, P., Kris-Etherton, P.M., West, S.G., et al., 2015. Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and lipoprotein-associated phospholipase A2 in individuals with moderate hypertriglyceridemia. Journal of Clinical Lipidology, 9(3), pp.360–367
9. Chan, D.C., Watts, G.F., Mori, T.A., Barrett, P.H.R., Redgrave, T.G. and Beilin, L.J., 2003. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. American Journal of Clinical Nutrition, 77(2), pp.300–307.
10. Blais, J.E., Nasir, K., An, N., et al., 2023. Overall and sex-specific effect of berberine for the management of lipids and apolipoprotein B in adults: a systematic review and meta-analysis of randomised controlled trials. Journal of Clinical Lipidology
11. Shidfar, F., Seyyed Ebrahimi, S., Hosseini, S., Heydari, I., Shidfar, S. and Hajhassani, G., 2013. The effects of Berberis vulgaris fruit extract on serum lipoproteins, apolipoprotein B, apolipoprotein A-I, homocysteine, and glycaemic control in type 2 diabetic patients: a randomised double-blind clinical trial. Journal of Medicinal Food
12. Minamizuka, T., Miwa, T., Watanabe, Y., et al., 2021. Low dose red yeast rice with monacolin K lowers LDL-cholesterol, total cholesterol and apolipoprotein B in patients with dyslipidaemia: a randomised controlled trial. Journal of Clinical Biochemistry and Nutrition
13. Zhang, Y.F., et al., 2024. Effects of phytosterol supplementation on lipid profiles and apolipoprotein B: systematic review and meta-analysis of randomised controlled trials. Medicine, 103(10180), pp.1-9